论文部分内容阅读
目的观察FOLFOX4方案治疗晚期胃癌的近期疗效和毒副反应。方法42例晚期胃癌患者接受FOLFOX4方案化疗,奥沙利铂85mg/m2,静脉滴注2h,d1;醛氢叶酸200mg/m2,静脉滴注2h,d1、d2;氟尿嘧啶400mg/m2,快速静脉滴注,d1、d2,600mg/m2,持续静脉滴注22h,d1、d2。每2周重复。4个周期后以WHO实体瘤疗效评定标准评价疗效及毒副反应。结果全组42例均可评价疗效,其中完全缓解(CR)1例,部分缓解(PR)19例,稳定(SD)14例,进展(PD)8例,总有效率(CR+PR)47.6%。中位肿瘤进展时间(TTP)为6个月,中位生存时间(MST)为9.5个月。毒副反应主要是骨髓抑制,白细胞降低发生率达80.9%,其次为胃肠道反应,恶心呕吐发生率78.6%,口腔黏膜炎19.0%,腹泻21.4%,无Ⅲ/Ⅳ度胃肠道反应;周围神经毒性发生率为66.7%。结论FOLFOX4方案治疗晚期胃癌的近期疗效较好,毒副反应可以耐受。
Objective To observe the short-term curative effect and toxicity of FOLFOX4 regimen in the treatment of advanced gastric cancer. Methods Forty-two patients with advanced gastric cancer received FOLFOX4 regimen, oxaliplatin 85mg / m2, intravenous drip 2h, d1, alforin 200mg / m2, intravenous drip 2h, d1, d2, 400mg / m2 fluorouracil Note, d1, d2, 600mg / m2, continuous intravenous infusion of 22h, d1, d2. Repeat every 2 weeks. After 4 cycles to evaluate the efficacy and toxicity of WHO solid tumors evaluation criteria. Results All the 42 patients were evaluated with complete remission (CR), partial remission (PR) in 19, stable (SD) in 14, progression (PD) in 8 and total effective rate (CR + PR) %. The median time to tumor progression (TTP) was 6 months and the median survival time (MST) was 9.5 months. The main side effects were myelosuppression, 80.9% leukopenia, followed by gastrointestinal reactions, nausea and vomiting 78.6%, oral mucositis 19.0%, diarrhea 21.4%, and no grade Ⅲ / Ⅳ gastrointestinal reactions. The incidence of peripheral neurotoxicity was 66.7%. Conclusion The FOLFOX4 regimen has a good short-term curative effect in treating advanced gastric cancer and its toxicity can be tolerated.